How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers

Amgen Inc. (AMGN) is a prominent biotechnology firm based in Thousand Oaks, California, that focuses on creating cutting-edge biologic medicines for severe conditions. Boasting a market capitalization of approximately $233.8 billion, AMGN stands as a mega-cap stock, indicative of its substantial size and influence within the general drug manufacturers industry.

Among its notable offerings are Repatha, Prolia, and Enbrel, alongside a rapidly expanding oncology pipeline. The company's success can be attributed to its strong product portfolio, impressive profitability, rapid sales growth, and adept international expansion.

However, AMGN has experienced a slight decline of 3.3% from its 52-week peak of $447.03, which was attained on August 25, 2026. Conversely, the stock has demonstrated remarkable performance over the past three months, soaring 28.5%, surpassing the Invesco Pharmaceuticals ETF (PJP) by 13.3%. Over the past year, AMGN stock has surged 51.4%, outpacing PJP's 40.2% gain.

AMGN's stock has remained above both its 50-day and 200-day moving averages since late June, indicating a consistent upward trend. On August 4, the company's shares rose approximately 2.9% following the release of its Q2 results, with adjusted EPS of $6.29 surpassing analysts' expectations of $5.60 and revenue of $10.05 billion exceeding forecasts of $9.44 billion.

Despite competing in a highly competitive industry, AMGN's top rival, Johnson & Johnson (JNJ), has underperformed, gaining just 29.5% year-to-date. However, JNJ has shown resilience over the past year, increasing by 52.8% and outperforming AMGN.

Wall Street analysts have a generally optimistic outlook on AMGN's prospects, assigning a 'Moderate Buy' rating to the stock, which is endorsed by 35 analysts covering it. The current share price is trading above the mean price target of $397.87. Kritika Sarmah, the author of this article, disclosed that she does not hold any positions in any of the securities mentioned. All information and data provided are for educational purposes only.